Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275463 | 0.76 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL15741938 | 0.72 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL21259853 | 0.72 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL11617 | 0.72 | FDPS (0.33) | NPC1 | |
| SCHEMBL7259774 | 0.72 | — | — | |
| SCHEMBL29852204 | 0.71 | DGAT1 (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL15032983 | 0.71 | DGAT1 (0.32) | DGAT1NPC1 | |
| Ammonia Solution, Strong SCHEMBL27898568 | 0.71 | FDPS (0.32) | — | |
| SCHEMBL24828271 | 0.71 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL26677486 | 0.71 | DGAT1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2008135767-A1 | NEW TRIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| EP-1943234-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | DGAT1 2336/4885EGFR 845/4885IGF1R 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.